华润双鹤子公司盐酸替罗非班氯化钠注射液获批上市

Core Viewpoint - China Resources Double Crane's subsidiary, Anhui Double Crane Pharmaceutical, has received approval for its sodium chloride injection of tirofiban hydrochloride, marking a significant addition to its product line [1] Company Summary - The drug received its registration certificate from the National Medical Products Administration on September 9, 2025, and is now officially approved for market launch [1] - The total R&D investment for this drug amounts to approximately 3.7558 million yuan [1] Market Summary - The estimated domestic market sales for the drug in 2024 are around 106 million yuan [1] - There are currently 18 companies approved to produce this drug, indicating a highly competitive market environment [1]